The post Bitcoin Holds Critical Range as Analysts Eye Next Major Breakout appeared on BitcoinEthereumNews.com. Bitcoin Analysis Bitcoin’s recent weakness relativeThe post Bitcoin Holds Critical Range as Analysts Eye Next Major Breakout appeared on BitcoinEthereumNews.com. Bitcoin Analysis Bitcoin’s recent weakness relative

Bitcoin Holds Critical Range as Analysts Eye Next Major Breakout

Bitcoin Analysis

Bitcoin’s recent weakness relative to gold and silver has sparked debate across macro and crypto circles, but analysts argue the relationship is being misunderstood.

Rather than needing precious metals to cool off before moving higher, Bitcoin appears to be working through its own structural reset.

Key Takeaways

  • Bitcoin is consolidating in a tight range rather than showing signs of structural weakness.
  • Analysts see no need for gold or silver to pull back for Bitcoin to regain upside momentum.
  • The $86,500-$90,000 zone remains the key battleground that will likely define Bitcoin’s next major move. 

Macro strategist Lyn Alden has repeatedly pushed back against the idea that Bitcoin competes directly with gold or silver. In her view, both assets respond to long-term monetary stress, but they move on different timelines. Gold tends to react first during periods of uncertainty, while Bitcoin often lags before catching up once liquidity conditions stabilize.

Why Gold Rallied First While Bitcoin Paused

That pattern helps explain why gold surged to fresh highs in 2025 while Bitcoin entered a prolonged consolidation phase instead of collapsing. The divergence, according to Alden, reflects timing rather than weakness.

From a market-structure perspective, Bitcoin’s behavior supports that view. After peaking above $125,000 in October, BTC entered a corrective phase that erased nearly 30% of its value. Unlike previous cycles, however, the decline did not turn into a disorderly selloff.

Bitcoin’s Price Structure Shows Compression, Not Breakdown

Price has repeatedly stabilized above the mid-$80,000 region, pointing to distribution and consolidation rather than panic. Volatility has compressed, and buyers continue to defend key levels despite broader macro uncertainty.

Technical indicators reinforce this interpretation. Bitcoin remains locked in a defined range between roughly $86,500 and $90,000. The RSI hovering in the low-to-mid 40s signals neutral momentum, while a flat, slightly negative MACD suggests downside pressure is fading rather than accelerating.

The Key Levels That Now Define Bitcoin’s Direction

Market analyst Michael van de Poppe highlighted the importance of this range, noting that $86,500 remains the critical downside pivot. A clean break below that level could open room for a deeper test toward the low $80,000s, potentially even the $80,000 zone.

On the flip side, reclaiming $90,000 would mark a meaningful shift in short-term structure. Such a move would push Bitcoin back above its 20-day moving average and likely attract momentum buyers, with the $100,000–$105,000 region emerging as the next major upside target.

Why Bitcoin May Not Need Gold to Cool Off

This technical stalemate is unfolding as gold and silver continue to absorb capital amid expectations of looser monetary policy, geopolitical risks, and a softer dollar outlook. For many analysts, that divergence is not bearish for Bitcoin, but preparatory.

Historically, periods where Bitcoin ranges while traditional hedges rally have often preceded renewed upside once capital rotates back toward digital assets.

A Base Is Forming, Even Without a Catalyst

Rather than waiting for precious metals to roll over, Bitcoin appears to be building its own foundation. Shrinking volatility, consistent dip buying, and clearly respected support and resistance levels suggest accumulation is quietly taking place.

If those conditions hold, analysts argue that Bitcoin does not need a signal from gold or silver to resume its longer-term trend.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Author

Kosta joined the team in 2021 and quickly established himself with his thirst for knowledge, incredible dedication, and analytical thinking. He not only covers a wide range of current topics, but also writes excellent reviews, PR articles, and educational materials. His articles are also quoted by other news agencies.

Source: https://coindoo.com/market/bitcoin-holds-critical-range-as-analysts-eye-next-major-breakout/

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.11688
$0.11688$0.11688
+0.49%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26